Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Recent biomarker analyses from our initial mouse DIO study have further extended ... CB1 inhibitor and the dual GLP-1 GIP agonist tirzepatide both alone and in combination with Nimacimab using ...

Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide ... Enhanced safety: Diet-induced obesity ("DIO”) mouse model data highlighted the sufficiency of the ...

Nimacimab in combination with tirzepatide improves weight loss ... Enhanced safety: Diet-induced obesity (“DIO”) mouse model data highlighted the sufficiency of the highly-peripherally ...

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...